Lviv clinical bulletin 2021, 1(33)-2(34): 8-13

Frequency of Arrhythmias and Conduction and Antiarrhythmic Efficacy of Upstream Therapy in Patients with Acute Myocardial Infarction with Comorbid Metabolic Syndrome and Vascular Endothelial Dysfunction

M. Shved, I. Yastremskaya, T. Dobriansky

I. Horbachevsky Ternopil National Medical University

Context. Cardiac arrhythmias and conduction disorders are the most common reperfusion complications in patients with myocardial infarction (MI) in both acute and late postinfarction periods, which significantly complicates the course of the disease and often leads to an unfavorable prognosis for the early and distant periods.

Objective. To evaluate the frequency of arrhythmias and conduction and the antiarrhythmic efficacy of upstream therapy in patients with acute MI with comorbid metabolic syndrome (MS) and endothelial vascular dysfunction.

Materials and methods. The experimental group consisted of 42 patients with acute myocardial infarction in combination with MS, who underwent urgent coronary angiography followed by balloon angioplasty and stenting of the infarct-dependent coronary artery, as well as standard drug therapy according to the MOH protocol. Patients in the experimental group also received 5 intravenous infusions of arginine-carnitine mixture (4.2 g and 2.0 g, respectively) in 100 ml of solvent. The nature of the clinical course of MI was compared with that in 38 patients with MI in combination with MS (control group), who did not receive additional treatment and were comparable in age (56.64 ± 0.91 and 54.85 ± 0.76 years, respectively).

Results. It was found that patients with MI with comorbid MS on percutaneous coronary intervention most often developed reperfusion syndrome with manifestations of arrhythmias and conduction. Under the influence of standard drug treatment in patients of the control group there was a significant clinical and functional improvement, though sinus tachycardia, ventricular extrasystole of high grades and supraventricular extrasystole remained resistant to treatment. There was also a pronounced endothelial vascular dysfunction, which in the process of standard treatment in patients of the control group did not reach the level of healthy individuals (p < 0.05).

Conclusions. In patients with acute MI with comorbid MS, who underwent balloon angioplasty and stenting of the infarct-dependent coronary artery, a pronounced vascular endothelial dysfunction and electrical instability is observed, accompanied by reperfusion arrhythmias and arrhythmias. The use of arginine-carnitine mixture as upstream therapy helped to restore endothelial function and showed a pronounced antiarrhythmic effect, which significantly reduced the incidence and severity of complications of acute MI such as reperfusion arrhythmias.


  1. Kostina VM, Ziuzin OV, Zinchenko TM. Metabolic syndrome: methods of diagnosis and rehabilitation. Ecology. 2011;152(140):76-78 (Ukrainian)
  2. Martyniuk HV, Skoreiko NT, Skoreiko RS, Skoreiko SS. Metabolic syndrome – some features of pathogenesis and its effect on the development of arterial hypertension. Bukovina Medical Journal. 2016;20(2):85-87 (Ukrainian)
  3. Myshchenko N. The Effect of L-arginine Supplementation on Blood Pressure in Patients with Type 2 Diabetes: A Double-Blind Randomized Clinical Trial. Diabetology, Thyroidology, Metabolic Disorders. 2017;2(38):26 (Ukrainian)
  4. Shved M, Pello M. Influence of cardioprotective metabolic therapy on the occurrence of rhythm and conduction disorders in patients with myocardial infarction with metabolic syndrome. Arithmology. 2018;2(26):53-55 (Ukrainian)
  5. Shved MI, Tsuglevich LV, Geryak SM. Clinical efficacy of cardiocytoprotective therapy in patients with acute coronary syndrome (myocardial infarction) who underwent balloon angioplasty and coronary artery stenting. Archive of Clinical Medicine. 2019;(1):31-37 (Ukrainian)
  6. Khobzei MK, Sirenko YuM, Stepanenko AV, Morozov AM, Amosova KM et al. Unified clinical protocol for emergency, primary, secondary and tertiary medikal care “Acute coronary syndrome with elevation of segment ST”. K.; 2014. 78 p. (Ukrainian).
  7. Khotina SH, Sokolov MYu, Parkhomenko OM, Lishchyshyna OM, Amosova KM et al. Unified clinical protocol of emergency, primary, secondary and tertiary medical care and medical rehabilitation “Acute coronary syndrome without elevation of the ST segment”. K.; 2015. 67 p. (Ukrainian).
  8. Bhar-Amato J, Davies W, Agarwal S. Ventricular Arrhythmia after Acute Myocardial Infarction: The Perfect Storm. Arrhythm Electrophysiol Rev. 2017;6(3):134-139.
  9. Catherine J , Cynthia J , Deepika R et al. Safety and Effectiveness of Arginine in Adults. J Nutr. 2016;146(12):2587S-2593S.
  10. Colonna P, Iliceto S. Myocardial infarction and left ventricular remodeling: Results of the CEDIM trial. Am Heart J. 2000;139(2):124-130.
  11. DiNicolantonio J, Lavie C, Fares H, Menezes A, O’Keefe J. L-Carnitine in the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis. Mayo Clin Proc. 2013;88(6):544-551.
  12. George J, Shmuel S, Roth A, Herz I, Izraelov S, Deutsch V et al. l-Arginine attenuates lymphocyte activation and anti-oxidized LDL antibody levels in patients undergoing angioplasty. Atherosclerosis. 2004;174(2):323-327.
  13. Gorenek B, Blomström Lundqvist C, Brugada Terradellas J et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA and EAPCI task force. EuroIntervention. 2015;10:1095-1108.
  14. McKnight JR, Satterfield MC, Jobgen WS, Smith SB, Spencer TE, Meininger CJ et al. Beneficial effects of L-arginine on reducing obesity: potential mechanisms and important implications for human health. Amino Acids. 2010;39:349-357.
  15. Paulson DJ. Carnitine deficiency-induced cardiomyopathy. Mol Cell Biochem. 1998;180(1,2):33-41.
  16. Popolo A, Adesso S, Pinto A, Autore G, Marzocco S. L-arginine and its metabolites in kidney and cardiovascular disease. Amino Acids. 2014;46:2271-2286.
  17. Suzuki T, Hirata K, Elkind MSV, Jin Z, Rundek T, Miyake Y et al. Metabolic Syndrome, Endothelial Dysfunction, and Risk of Cardiovascular Events: the Northern Manhattan Study. Am Heart J. 2008;156(2):405-410.
  18. Wang ZY, Liu YY, Liu GH, Lu HB, Mao CY. l-Carnitine and heart disease. Mao CY. Life Sci. 2018;194:88-97.
  19. Widmer J, Lerman A. Endothelial dysfunction and cardiovascular disease. Glob Cardiol Sci Pract. 2014(3):291-308.